Cardiff Oncology released interim results from its randomized Phase 2 CRDF-004 trial evaluating onvansertib combined with standard chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer. The trial data may impact the company's clinical development pathway and commercial prospects for this oncology candidate.